FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

benzinga.com/news/fda/25/08/47214137/fda-extends-decision-date-on-regenxbios-gene-therapy-into-next-year

The U.S. Food and Drug Administration (FDA) on Monday extended its review timeline for REGENXBIO Inc.’s (NASDAQ:RGNX) Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) for Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome.
The Prescription Drug…

This story appeared on benzinga.com, 2025-08-19 16:01:09.
The Entire Business World on a Single Page. Free to Use →